Reading view
ConSensus: Multi-Agent Collaboration for Multimodal Sensing
Why Slop Matters
The Patient/Industry Trade-off in Medical Artificial Intelligence
$\texttt{AMEND++}$: Benchmarking Eligibility Criteria Amendments in Clinical Trials
A Large-Scale Study on the Development and Issues of Multi-Agent AI Systems
Learning from Reasoning Failures via Synthetic Data Generation
FairMedQA: Benchmarking Bias in Large Language Models for Medical Question Answering
From Wearables to Warnings: Predicting Pain Spikes in Patients with Opioid Use Disorder
Reqo: A Comprehensive Learning-Based Cost Model for Robust and Explainable Query Optimization
Anthropic announces Claude for Healthcare following OpenAI’s ChatGPT Health reveal
Key Information Influencing Patient Decision-Making About AI in Health Care: Survey Experiment Study
Interpretable inflammation landscape of circulating immune cells
Nature Medicine, Published online: 12 January 2026; doi:10.1038/s41591-025-04126-3
Including data from 1,047 patients across 19 inflammatory diseases, a new atlas presents a comprehensive model of inflammation in circulating immune cells.The Evaluation Gap in Medicine, AI and LLMs: Navigating Elusive Ground Truth & Uncertainty via a Probabilistic Paradigm
A Survey of Agentic AI and Cybersecurity: Challenges, Opportunities and Use-case Prototypes
Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making
Cancers (Basel). 2025 Dec 27;18(1):94. doi: 10.3390/cancers18010094.
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with poor long-term survival despite advances in surgical techniques, systemic therapies, and perioperative management. High rates of systemic recurrence following curative-intent resection suggest that many patients harbor minimal residual disease (MRD), microscopic tumor burden that persists postoperatively and remains undetectable by conventional diagnostic tools. Recent advances in liquid biopsy technologies, particularly circulating tumor DNA (ctDNA) analysis, alongside detailed characterization of the PDAC mutational landscape, offer a promising non-invasive approach for MRD detection. Emerging evidence indicates that MRD status can serve as a sensitive prognostic biomarker, identify patients at high risk of relapse, and guide personalized perioperative therapy, including optimization of adjuvant treatment. This review summarizes current knowledge on the biology and detection of MRD in PDAC, its implications for perioperative risk stratification and treatment decision-making, and discusses future directions for integrating MRD assessment into clinical practice to enable more precise, individualized patient management.
PMID:41514607 | PMC:PMC12784771 | DOI:10.3390/cancers18010094
BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial
Nature Medicine, Published online: 09 January 2026; doi:10.1038/s41591-025-04170-z
Analysis of a placebo-controlled trial of a BCMA-targeting CAR-T cell therapy in patients with myasthenia gravis shows that CAR-T cell infusion selectively remodels the systemic immune environment, with elimination of BCMA-high plasma cells and activated plasmacytoid dendritic cells and changes in the autoreactive B cell repertoire.BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial
Nature Medicine, Published online: 09 January 2026; doi:10.1038/s41591-025-04171-y
In a randomized, double-blind, placebo-controlled trial comparing autologous mRNA-engineered BCMA-targeting CAR T cell therapy versus placebo in patients with generalized myasthenia gravis, a significantly higher percentage of patients exhibited a reduction in disease activity in the treatment arm than in the placebo arm.